Memory-Like Natural Killer Cell and CD19-Antibody Based Immunotherapy in Combination with Tyrosine-Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia

Investigators explored the potential of memory-like natural killer cells and Fc-enhanced CD19-ADCC in combination with tyrosine kinase inhibitor directed against kinase-driven leukemia models, including patient-derived xenografted Philadelphia-like acute lymphoblastic leukemia (Ph-like ALL).